Arcellx: CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma

 -- Abstract released today is from a June 2, 2023 data cut --

-- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA infusion of 22 months --

-- A more recent data cut will be shared during the oral presentation with a median follow-up of 26.5 months --

-- Company to host a live webcast event with an expert panel of clinicians --

Webcast Event:
Arcellx will host a live webcast event with an expert panel of clinicians to discuss the clinical results on Monday, December 11, 2023 at 8 p.m. PT. The event will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.

https://www.prnewswire.com/news-releases/arcellx-announces-oral-presentation-for-its-cart-ddbcma-phase-1-trial-in-patients-with-relapsed-or-refractory-multiple-myeloma-at-the-65th-ash-annual-meeting-and-exposition-301975098.html